



Croat. Chem. Acta **2017**, 90(4), 603–611
Published online: April 11, 2018
DOI: 10.5562/cca3269



Impact of the Supramolecular Organisation of Pyrene – Quinoline Conjugates on their Interaction with ds – DNA

Iva Orehovec,² Danijel Glavač,¹ Irena Dokli,³ Matija Gredičak,¹ Ivo Piantanida^{*,2}

¹ Laboratory for Biomimetic Chemistry, Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička c. 54, HR-10000, Zagreb, Croatia

² Laboratory for Biomolecular Interactions and Spectroscopy, Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička c. 54, HR-10000, Zagreb, Croatia

³ Laboratory for stereoselective catalysis and biocatalysis, Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička c. 54, HR-10000, Zagreb, Croatia

* Corresponding author's e-mail address: pianta@irb.hr

RECEIVED: December 11, 2017 * REVISED: February 14, 2018 * ACCEPTED: March 26, 2018

THIS PAPER IS DEDICATED TO PROF. MLADEN ŽINIĆ ON THE OCCASION OF HIS 70TH BIRTHDAY

Abstract: Two novel pyrene – quinoline conjugates differing in the linker flexibility between aryls were prepared. In comparison with referent pyrene derivative, both conjugates showed intramolecular pyrene – quinoline stacking in aqueous medium, much more efficient for rigid conjugate. Consequently, only rigid conjugate showed excimer fluorescence with exceptionally strong bathochromic shift (+ 55 nm) of emission maximum in respect to referent pyrene analogue and flexible conjugate. All studied compounds showed similar, 10 $\mu\text{mol dm}^{-3}$ affinity toward ds – DNA, characterised in general by fluorescence quenching. The flexible conjugate showed at large excess of DNA over dye formation of pyrene – quinoline excimer, while rigid conjugate retained excimer emission throughout all DNA concentrations. Lack of significant thermal stabilisation of ds – DNA by studied compounds and minor changes in CD spectrum of DNA supported non – specific agglomeration of both conjugates and referent pyrene analogue within hydrophobic DNA grooves as the dominant binding mode.

Keywords: pyrene, quinoline, fluorescence, DNA recognition, excimer emission.


INTRODUCTION

SMALL molecules which could selectively report on small structural differences of DNA as well as RNA secondary structure or their higher ordered structures are of significant scientific interest as molecular tools and probes.^[1] There are several dominant non – covalent binding modes of small molecule to ds – DNA / RNA: intercalation, groove binding and electrostatic interactions with negatively charged phosphate backbone, each of them with certain advantages and pitfalls. Therefore, many researchers designed molecules combining two or more dominant binding interactions aiming toward improved selectivity.

One of the extensively used polarity – sensitive probes is pyrene: its fluorescence has been employed for the characterisation of micro – heterogeneous systems.^[2] A long lifetime of the excited state and the possibility of easy excimer formation^[3] are distinctive features of the pyrene

fluorophore that allow its application for detection of nucleic acid interactions both as a single label^[4] and in excimer – forming pairs or as multi – pyrene probes.^[5] Moreover, the flat aromatic structure of the pyrene residue facilitates its stacking with nucleobases.^[6] However, intercalative binding of pyrene to DNA / RNA has very limited selectivity and thus pyrene most interesting applications relied on its interactions within the DNA or RNA grooves^[7] or were combined with switch – on and – off of pyrene excimer.^[8] The short peptides and peptidomimetics, including condensed aromatic peptide conjugates, could be designed to bind to DNA / RNA, whereby peptide backbone is not only structural component directing DNA – targeting units but also can actively interact within polynucleotide groove by set of hydrogen – bonding and hydrophobic interactions.^[9,10]

In a search for new small molecules targeting DNA we noted intriguing properties of helical foldamers based



Scheme 1. Novel pyrene – quinoline conjugates **7**, **8** and referent pyrene analogue **4**.

on quinoline amides, which interacted efficiently with DNA.^[11] This raised a question whether the heterogeneous conjugate made of pyrene and quinoline would show different DNA binding properties, due to the altered intramolecular folding of two different aromatic moieties. As a preliminary study we prepared two pyrene – quinoline dimers (Scheme 1, **7** and **8**) differing slightly in peptide linker length and rigidity to test fine structural impact, and also a referent pyrene analogue **4** for comparison. All derivatives are equipped with positively charged aliphatic amine group for increased water solubility and also additional electrostatic interactions with DNA backbone.

EXPERIMENTAL SECTION

General Information

Unless otherwise indicated, solvents were used as supplied (analytical or HPLC grade) without further purification. “Petrol” or “petroleum ether” refers to the fraction of petroleum ether boiling in the range 40–60 °C. Where mixtures of solvents are specified, the stated ratios are

volume: volume. Unless otherwise indicated, all aqueous solutions used were saturated. Reagents were used directly as supplied by major chemical suppliers.

Flash column chromatography was carried out using silica gel (Merck, 40–63 μ m particle size). Analytical thin – layer chromatography was carried out on Merck Kieselgel 60 F254 0.25 mm precoated aluminium plates. Visualization was carried out under ultra – violet irradiation (254 nm) and by appropriate heating with ammonium molybdate. Ammonium molybdate solution was prepared by dissolving ammonium molybdate (5 g) and ceric sulfate (0.2 g) in 5 % aqueous sulfuric acid (100 mL).

NMR spectra were recorded on Bruker Avance 600 MHz and 300 MHz spectrometers, operating at 150.92 or 75.47 MHz for ^{13}C and 600.13 or 300.13 MHz for ^1H nuclei. Chemical shifts are quoted in ppm, and are referenced to the residual non – deuterated solvent peak. ^1H spectra are reported as follows: ^1H NMR (spectrometer frequency, solvent): δ chemical shift / ppm (multiplicity, number of protons, J – coupling constant(s), assignment). ^{13}C spectra are reported as follows: ^{13}C NMR (spectrometer frequency, solvent): δ chemical shift / ppm (assignment). Multiplets are abbreviated as follows: s – singlet; d – doublet; t – triplet; q – quartet; m – multiplet, and are reported based on appearance rather than interpretation. Compound multiplets are reported in the order of decreasing coupling constant magnitude. Spectra were acquired at 298 K.


Mass spectrometry measurements were performed on HPLC system coupled with triple quadrupole mass spectrometer, operating in a positive electrospray ionization (ESI) mode.

Melting points were determined using an Electrothermal 9100 apparatus in open capillaries and are uncorrected.

Where given, systematic compound names are those generated by ChemBioDraw Ultra 12.0 following IUPAC conventions. Spectral assignment purpose is arbitrary and not necessarily consistent with the IUPAC names (Scheme 2).

Tert-butyl(2-oxo-2-(pyren-2-ylamino)ethyl)carbamate (**1**)

Pyren-2-amine (100 mg, 0.46 mmol), *N*-Boc-glycine (80 mg, 0.46 mmol) and triethylamine (77 μ L, 0.55 mmol) were mixed in DMF (10 mL) under argon. (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent, 224 mg, 0.55 mmol) was added, and the reaction mixture was stirred overnight at room temperature. Saturated aqueous solution of NH_4Cl (10 mL) was added, and the mixture extracted with diethyl ether (3 \times 5 mL). Organic layers were combined, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The product was obtained by flash column chromatography in dichloromethane – methanol 1 : 0 \rightarrow 20 : 1 as a brown solid.



Scheme 2. Synthesis of pyrene conjugates 4, 7, 8.

Yield: 85 mg (50 %). m.p. 159 – 161 °C. ^1H NMR (600 MHz, CDCl_3) δ /ppm: 9.06 (s, 1H), 8.18 (d, $J = 6.5$ Hz, 1H), 8.02 (d, $J = 7.4$ Hz, 1H), 7.93 (d, $J = 7.4$ Hz, 1H), 7.87 (t, $J = 6.4$ Hz, 1H), 7.82 (m, 3H), 7.74 (m, 2H), 5.76 (t, $J = 5.7$ Hz, 1H), 4.15 (s, 2H), 1.54 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3) δ /ppm: 169.0, 156.9, 131.1, 130.5, 129.7, 128.9, 127.6, 127.0, 126.6, 125.9, 125.2, 124.8, 124.7, 124.4, 123.2, 121.7, 120.2, 80.8, 45.8, 28.4. ESI-MS: m/z 375 $[\text{M}+\text{H}]^+$.

***Tert*-butyl(2-oxo-2-((pyren-1-ylmethyl)amino)ethyl)carbamate (2)**

Pyren-2-ylmethanamine (100 mg, 0.37 mmol), *N*-Boc-glycine (65 mg, 0.37 mmol) and triethylamine (115 μL , 0.82 mmol) were mixed in DMF (10 mL) under argon. (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent, 181.5 mg, 0.41 mmol) was added, and the reaction mixture was stirred overnight at room temperature. Saturated aqueous solution of NH_4Cl

(10 mL) was added, and the mixture extracted with diethyl ether (3×5 mL). Organic layers were combined, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The product was obtained by flash column chromatography in ethyl acetate – petroleum ether 1 : 1 as a yellow solid. Yield: 136 mg (95 %). m.p. 164–167 °C. ^1H NMR (600 MHz, CDCl_3) δ /ppm: 8.16 (d, $J = 7.6$ Hz, 3H), 8.11–8.06 (m, 2H), 8.05–7.97 (m, 3H), 7.89 (d, $J = 7.7$ Hz, 1H), 6.60 (s, 1H), 5.20 (s, 1H), 5.09 (d, $J = 5.2$ Hz, 2H), 3.83 (s, 2H), 1.33 (s, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ /ppm: 169.2, 156.1, 131.2, 130.7, 130.6, 128.9, 128.3, 127.5, 127.3, 126.9, 126.1, 125.4, 125.3, 124.9, 124.7, 124.6, 122.6, 80.3, 44.5, 41.7, 28.2. ESI-MS: m/z 389 $[\text{M}+\text{H}]^+$.

2-oxo-2-(pyren-2-ylamino)ethanaminium-2,2,2-trifluoroacetate (3)

Tert-butyl(2-oxo-2-(pyren-2-ylamino)ethyl)carbamate **1** (50 mg, 0.13 mmol) was dissolved in 90 % trifluoroacetic

acid (3 mL). Reaction mixture was stirred for 2 hours and then triturated with diisopropyl ether to obtain crude compound **3**. Yield: 48 mg (94 %). m.p. 260–263 °C. ^1H NMR (600 MHz, DMSO) δ /ppm: 10.80 (s, 1H), 8.38–8.31 (m, 3H), 8.31–8.25 (m, 2H), 8.24–8.19 (m, 3H), 8.12 (t, $J = 7.5$ Hz, 1H), 4.09 (s, 2H). ^{13}C NMR (151 MHz, DMSO) δ /ppm: 166.4, 131.3, 131.0, 130.9, 129.1, 127.9, 127.7, 127.4, 127.1, 126.0, 125.6, 125.6, 124.8, 124.4, 124.2, 123.4, 122.6, 41.5. ESI-MS: m/z 275 $[\text{M}+\text{H}]^+$.

2-oxo-2-((pyren-1-ylmethyl)amino)ethanaminium-2,2,2-trifluoroacetate (4)

Tert-butyl(2-oxo-2-((pyren-1-ylmethyl)amino)ethyl)carbamate **2** (110 mg, 0.28 mmol) was dissolved in 90 % trifluoroacetic acid (3 mL). Reaction mixture was stirred for 2 hours and then triturated with diisopropyl ether to obtain crude compound **4** as brown solid. Yield: 108 mg (95 %). m.p. 214–218 °C. ^1H NMR (600 MHz, DMSO) δ /ppm: 9.07 (s, 1H), 8.37 (d, $J = 9.2$ Hz, 1H), 8.35–8.23 (m, 4H), 8.17 (s, 2H), 8.12 (s, 2H), 8.10–8.04 (m, 2H), 5.09 (d, $J = 5.5$ Hz, 2H), 3.65 (s, 2H). ^{13}C NMR (75 MHz, DMSO) δ /ppm: 166.4, 132.4, 131.2, 130.7, 130.7, 128.6, 128.2, 127.8, 127.7, 127.28, 126.8, 125.8, 125.7, 125.2, 124.5, 124.3, 123.6, 41.0, 40.7. ESI-MS: m/z 289 $[\text{M}+\text{H}]^+$.

***Tert*-butyl-3-((8-nitro-2-((2-oxo-2-(pyren-2-ylamino)ethyl)carbamoyl)quinolin-4-yl)oxy)propyl)carbamate (5)**

4-(3-(*tert*-Butoxycarbonylamino)propoxy)-8-nitroquinoline-2-carboxylic acid **4**^[11] (20 mg, 0.05 mmol), compound **3** (20 mg, 0.05 mmol), and triethylamine (20 μL , 0.15 mmol) were dissolved in DMF (2 mL) under argon. (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent, 24 mg, 0.05 mmol) was added, and the reaction was stirred over night at room temperature. Saturated aqueous solution of NH_4Cl (10 mL) was added, and the mixture extracted with diethyl ether – ethyl acetate 1 : 1 (3 \times 5 mL). Organic extracts were combined, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. Crude product was purified by column chromatography on silica gel with ethyl acetate – petroleum ether – dichloromethane 3 : 1 : 2 to afford product **5** as brown oil. Yield: 18 mg (56 %). ^1H NMR (600 MHz, CDCl_3) δ /ppm: 9.12 (s, 1H), 8.96 (s, 1H), 8.49 (m, 2H), 8.26 (d, $J = 7.8$ Hz, 1H), 8.20–8.11 (m, 6H), 8.00 (m, 3H), 7.85 (s, 1H), 7.66 (t, $J = 8.0$ Hz, 1H), 4.58 (d, $J = 6.3$ Hz, 2H), 4.41 (s, 2H), 3.43 (s, 2H), 2.18 (s, 2H), 1.59 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3) δ /ppm: 167.7, 165.4, 163.7, 163.2, 155.9, 147.8, 142.1, 139.1, 135.5, 131.3, 130.8, 128.1, 127.4, 126.8, 126.7, 126.7, 126.1, 125.8, 125.4, 125.2, 125.1, 125.0, 123.2, 122.7, 121.8, 120.3, 99.9, 77.2, 67.4, 45.5, 37.6, 29.7, 28.4, one aromatic carbon not observed. ESI-MS: 648 $[\text{M}+\text{H}]^+$.

***Tert*-butyl-3-((8-nitro-2-((2-oxo-2-(pyren-1-ylmethyl)amino)ethyl)carbamoyl)quinolin-4-yl)oxy)propyl)carbamate (6)**

4-(3-(*tert*-Butoxycarbonylamino)propoxy)-8-nitroquinoline-2-carboxylic acid **4**^[11] (13 mg, 0.03 mmol), compound **10** (13 mg, 0.03 mmol), and triethylamine (14 μL , 0.10 mmol) were dissolved in DMF (2 mL) under argon. (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent, 16 mg, 0.04 mmol) was added, and the reaction was stirred over night at room temperature. Saturated aqueous solution of NH_4Cl (10 mL) was added, and the mixture extracted with diethyl ether – ethyl acetate 1 : 1 (3 \times 5 mL). Organic extracts were combined, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. Crude product was purified by column chromatography on silica gel with ethyl acetate – petroleum ether – dichloromethane 3 : 1 : 2 to afford product **6** as yellow oil. Yield: 13 mg (60 %). ^1H NMR (600 MHz, DMSO) δ /ppm: 8.79–8.73 (m, 2H), 8.47 (dd, $J = 8.4$, 1.2 Hz, 1H), 8.40 (d, $J = 9.2$ Hz, 1H), 8.37 (dd, $J = 7.5$, 1.3 Hz, 1H), 8.32–8.24 (m, 4H), 8.17 (m, 2H), 8.12–8.05 (m, 2H), 7.84–7.78 (m, 1H), 7.72 (s, 1H), 6.97 (t, $J = 5.3$ Hz, 1H), 5.08 (d, $J = 5.7$ Hz, 2H), 4.41 (t, $J = 6.1$ Hz, 2H), 4.13 (d, $J = 5.7$ Hz, 2H), 3.21 (dd, $J = 12.5$, 6.3 Hz, 2H), 2.05–1.99 (m, 2H), 1.34 (s, 9H). ^{13}C NMR (151 MHz, DMSO) δ /ppm: 168.7, 163.8, 163.1, 156.1, 153.5, 148.2, 138.6, 133.1, 131.3, 130.8, 130.6, 128.5, 128.1, 127.9, 127.5, 127.1, 126.8, 126.7, 126.5, 125.7, 125.6, 125.4, 125.2, 124.5, 124.4, 123.6, 122.8, 100.6, 78.0, 67.8, 43.1, 40.9, 37.2, 29.2, 28.7. ESI-MS: 662 $[\text{M}+\text{H}]^+$.

3-((8-nitro-2-((2-oxo-2-(pyren-2-ylamino)ethyl)carbamoyl)quinolin-4-yl)oxy)propan-1-aminium-2,2,2-trifluoroacetate (7)

Compound **5** (10 mg, 0.02 mmol) was dissolved in 90 % trifluoroacetic acid (3 mL). Reaction mixture was stirred for 2 hours and then triturated with diisopropyl ether to obtain crude compound **7** as grey solid. Yield: 9 mg (85 %). m.p. 160–163 °C. ^1H NMR (600 MHz, DMSO) δ /ppm: 10.56 (s, 1H), 8.94 (s, 1H), 8.54 (d, $J = 8.5$ Hz, 1H), 8.40 (m, 2H), 8.30 (t, $J = 7.2$ Hz, 3H), 8.25 (d, $J = 9.2$ Hz, 1H), 8.22–8.13 (m, 2H), 8.09 (t, $J = 7.6$ Hz, 1H), 7.89–7.76 (m, 4H), 4.60–4.39 (m, 4H), 3.12 (d, $J = 6.1$ Hz, 2H), 2.23 (m, 2H). ^{13}C NMR (151 MHz, DMSO) δ /ppm: 168.6, 166.1, 163.9, 162.9, 158.3, 148.2, 138.6, 138.0, 131.3, 130.9, 128.8, 127.7, 127.7, 127.6, 127.6, 127.1, 127.1, 126.9, 126.9, 125.8, 125.5, 125.4, 124.8, 124.3, 122.8, 122.7, 100.9, 67.0, 43.7, 36.7, 26.9. ESI-MS: m/z 548 $[\text{M}+\text{H}]^+$.

3-((8-nitro-2-((2-oxo-2-(pyren-1-ylmethyl)amino)ethyl)carbamoyl)quinolin-4-yl)oxy)propan-1-aminium-2,2,2-trifluoroacetate (8)

Compound **6** (10 mg, 0.02 mmol) was dissolved in 90 % trifluoroacetic acid (3 mL). Reaction mixture was stirred for

2 hours and then triturated with diisopropyl ether to obtain crude compound **8** as grey solid. Yield: 8 mg (95 %). m.p. 164–167 °C. ^1H NMR (600 MHz, DMSO) δ /ppm: 8.78 (s, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.40 (dd, J = 11.6, 8.6 Hz, 2H), 8.34 – 8.23 (m, 4H), 8.17 (s, 2H), 8.09 (t, J = 7.4 Hz, 2H), 7.92 – 7.78 (m, 4H), 7.75 (s, 1H), 5.09 (d, J = 5.4 Hz, 2H), 4.51 (t, J = 5.6 Hz, 2H), 4.13 (d, J = 5.6 Hz, 2H), 3.11 (d, J = 5.9 Hz, 2H), 2.27 – 2.15 (m, 2H). ^{13}C NMR (151 MHz, DMSO) δ /ppm: 168.7, 163.7, 162.9, 153.5, 148.2, 138.6, 133.1, 131.3, 130.8, 130.6, 128.5, 128.1, 127.8, 127.5, 127.1, 126.9, 126.7, 126.5, 125.7, 125.6, 125.5, 125.2, 124.5, 124.4, 123.6, 122.7, 100.8, 67.0, 43.0, 40.9, 36.7, 26.9. ESI-MS: m/z 563 $[\text{M}+\text{H}]^+$.

UV-Visible Spectrophotometry, Circular Dichroism (CD) and Fluorescence Spectroscopy

The UV-Vis spectra were recorded on a Varian Cary 100 Bio or CECIL Aurius 3021 spectrophotometer, fluorescence spectra on a Varian Cary Eclipse fluorescence spectrophotometer and CD spectra were collected with a Jasco J – 815 spectropolarimeter at 25 °C using 1 cm path quartz cuvettes.

The *calif thymus* ct – DNA (Sigma – Aldrich, St. Louis, USA) was dissolved in sodium cacodylate buffer, I = 0.05 mol dm $^{-3}$, pH = 7, additionally sonicated and filtered through a 0.45 μm filter. The polynucleotide concentration was determined spectroscopically as the concentration of phosphates, which also corresponds to the concentration of mol nucleobase / L.^[12] Aqueous solutions of compounds were buffered to pH = 7 (sodium cacodylate buffer, I = 0.05 mol dm $^{-3}$). Spectrophotometric titrations were performed at pH = 7.0 (sodium cacodylate buffer, I = 0.05 mol dm $^{-3}$) by adding portions of DNA solution into the solution of the studied compound. The CD experiments were performed by adding aliquots of the aqueous solutions of compounds into the solution of polynucleotide. In fluorimetric experiments the excitation wavelength above 300 nm (λ_{exc} = 343 nm) was used to avoid the possible inner filter effect caused by increasing absorbance of the polynucleotide.

Thermal Denaturation Experiments

Thermal denaturation experiments for ct – DNA and its complexes with studied compounds were carried out by following the change in the absorption at 260 nm as a function of temperature. The absorbance of the ligands was subtracted from each curve and the absorbance scale was normalized. T_m values are the midpoints of the transition curves, determined from the maximum of the first derivative and checked graphically by the tangent method.^[13] The ΔT_m values were calculated subtracting T_m of the free nucleic acid from T_m of the complex. The ΔT_m values (error \pm 0.5 °C) reported are the average of at least duplicate measurements.




Figure 1. UV-Vis spectra of **4**, **7**, **8** at $c = 1 \times 10^{-6}$ mol dm $^{-3}$, in water.

RESULTS AND DISCUSSION

Compounds **4**, **8** were moderately soluble in redistilled water ($c = 1 \times 10^{-3}$ mol dm $^{-3}$), while compound **7** due to poor aqueous solubility was dissolved in DMSO and used as a stock solution. For accurate measurements fresh solutions were prepared daily.

The UV-Vis spectra of the compounds' aqueous solutions are proportional to their concentration up to 2 $\mu\text{mol dm}^{-3}$ concentration, molar extinction coefficients are given in Table 1.

Closer analysis of the UV-Vis spectra presented on Figure 1 (collected at 1 $\mu\text{mol dm}^{-3}$ concentration to avoid intermolecular aggregation) revealed significant differences between referent **4** and conjugates **7** and **8**. Namely, UV-Vis spectrum of referent **4** agrees well with the spectrum of free pyrene derivatives in water,^[2,4] characterised by three sharply defined maxima between 300–350 nm. However, conjugate **8** revealed strong hypochromic effect and broadening of maxima accompanied by small bathochromic shift ($\Delta\lambda = +3$ nm). For conjugate **7** hypochromic effect and broadening of maxima was even more pronounced, to the point of merging three maxima in one (in 300–350 nm range). The observed differences could be attributed to the intramolecular

Table 1. Electronic absorption data of **4**, **7** and **8** determined from data on Figure 1

	$\lambda_{\text{max}} / \text{nm}$	$\varepsilon \times 10^3 / \text{mmol}^{-1} \text{cm}^2$
4	341	34.631
7	341	7.040
8	343	18.270




Figure 2. The fluorescence emission spectra of **4**, **7**, **8** ($c = 1 \mu\text{mol dm}^{-3}$) in buffered solution, pH = 7, buffer Na cacodylate, $I = 0.05 \text{ M}$, $\lambda_{\text{exc}} = 343 \text{ nm}$.

stacking between pyrene and quinoline, whereby more flexible linker of **8** revealed less efficient self – stacking in comparison to more rigid **7**.

These findings were additionally supported by UV-Vis spectra thermal stability studies by heating to 95°C , whereby for referent **4** showed negligible changes, conjugate **8** revealed only minor changes, and stronger changes were observed for the **7** (Supporting Information).

Aqueous solutions of studied compounds exhibited strong fluorescence emission (Figure 2) upon excitation at pyrene absorbance maximum ($\lambda_{\text{exc}} = 343 \text{ nm}$). Again, referent **4** exhibited emission spectrum with finely distinguishable vibronic bands (375, 395, 417 nm) characteristic for the free pyrene in water.^[2,4] The conjugate **8** emission spectrum lost fine vibronic structure and had only one maximum at 390 nm, which could be attributed to partial intramolecular stacking with quinoline. The most intriguing is the emission spectrum of **7**, with one broad maximum bathochromically shifted for about $\Delta\lambda = +60 \text{ nm}$ in respect to **4** and **8**. It is well – known that two pyrenes upon excitation can form aromatically stacked complex – excimer, with characteristic fluorescence emission in the 490–500 nm range.^[4,8] However, conjugate **7** consists of pyrene and quinoline, thus strongly shifted emission maximum could be attributed to pyrene – quinoline excimer. Formation of such heterogenic excimer in **7** was additionally supported by its emission maximum at 450 nm, whereas pyrene – pyrene excimer emission maximum is at $\lambda > 490 \text{ nm}$.^[8b]

Interactions of **4**, **7**, **8** with ds – DNA

Compounds **4**, **7** and **8** were further studied in buffered solution (sodium cacodylate buffer, $I = 0.05 \text{ mol dm}^{-3}$) at pH = 7. As a ds – DNA model was used mixed sequence *cal*f




Figure 3. UV-Vis titration of **4** ($c = 1 \times 10^{-5} \text{ mol dm}^{-3}$) with ct – DNA, $\log K_s = 5.3 \text{ M}^{-1}$; $n_{[\text{bound } 4]} / [\text{ctDNA}] = 0.3$. Done at pH 7.0, sodium cacodylate buffer.

thymus ct – DNA, which is characterised by almost equimolar basepair content (42 % GC –; 58 % AT – basepairs) and B – helical secondary structure.^[14]

The UV-Vis titrations were partially hampered by low solubility of compounds and / or their complexes with DNA. Only referent **4** yielding the UV-Vis titration data (Figure 3), which could be processed by Scatchard eq.^[15] to yield binding constant and Scatchard ratio $n_{[\text{bound dye}]} / [\text{DNA}]$.

Detailed analysis of changes in UV-Vis spectrum of **4** (Figure 3) or **7** (Supp. Info., done at significantly lower concentrations due to low solubility) revealed that formation of complex with ct – DNA caused strong hypochromic ($> 50 \%$) and bathochromic ($\Delta\lambda = +15 \text{ nm}$) effects. Such effects are characteristic for strong aromatic stacking of chromophore, either due to the aromatic interactions with nucleobases or due to the aggregation of chromophores along DNA double helix. To discern between two opposing binding modes, additional methods are needed, which would accurately determine affinity of small molecule to DNA,^[15] as well as compound impact on thermal stability^[13] and chirality^[18] of DNA double helix.

The intrinsic pyrene fluorescence allowed fluorimetric titrations of **4**, **7**, **8** to be performed at much lower concentrations than UV-Vis experiments, thus avoiding solubility problems. In general, fluorescence of studied compounds at their emission maxima was quenched upon addition of ct – DNA. However, each compound showed distinctively different fluorescence change, which would be discussed in detail.

Referent **4** fluorescence (Figure 4A) was almost completely quenched, whereby all maxima similarly decreased with no significant shifting. The conjugate **8** showed significantly different emission change (Figure 4B), whereby quenching of pyrene fluorescence at 389 nm was




Figure 4. Changes in fluorescence spectrum of A) **4**; B) **8**; C) **7**; ($c(\text{ligand}) = 1.0 \times 10^{-6} \text{ mol dm}^{-3}$) upon titration with ct – DNA; $\lambda_{\text{exc}} = 343 \text{ nm}$. Insets: Dependence of fluorescence intensity at emission maxima on $c(\text{ct – DNA})$ at pH 7.0, sodium cacodylate buffer, $I = 0.05 \text{ mol dm}^{-3}$.

accompanied by appearance of a new emission maximum strongly shifted to longer wavelength ($\Delta\lambda = + 55 \text{ nm}$). Detailed analysis of titration data revealed that in the range of ratio $r_{[\text{8}]} / [\text{ctDNA}] = 0.5\text{--}0.02$ isosbestic point at 411 nm was evident, thus supporting formation of only one type of **8** /

Table 2. Binding constants ($\log K_s$)^(a) calculated from the fluorescence titrations ($\lambda_{\text{exc}} = 343 \text{ nm}$) of **4**, **7** and **8** with ct – DNA at pH = 7.0 (buffer sodium cacodylate, $I = 0.05 \text{ mol dm}^{-3}$)

	4	7	8
$\log K_s$ ^(a)	5.5 (5.3 ^(b))	5.9	4.9

^(a) Processing of titration data by means of Scatchard equation^[15] gave values of ratio $n_{[\text{bound ligand}]} / [\text{ct – DNA}] = 0.1\text{--}0.3$, for easier comparison all $\log K_s$ values were re – calculated for fixed $n = 0.3$. Correlation coefficients were > 0.99 for all calculated K_s .

^(b) Binding constant calculated from UV-Vis titration, Figure 3.

DNA complex (these data were processed by Scatchard eq.^[15] to give binding constant). Only at large excess of DNA over **8** ($r_{[\text{8}]} / [\text{ctDNA}] = 0.01\text{--}0.001$) the new maximum ($\lambda_{\text{max}} = 445 \text{ nm}$) strongly increased, whereby isosbestic point was lost, pointing out to the appearance of another type of complex. As mentioned before, pyrene excimer fluorescence is characterised by maximum at 490–500 nm,^[8b] while here observed emission at 445 nm could be attributed to pyrene – quinoline excimer.

The conjugate **7** has intrinsic fluorescence emission maximum at $\lambda = 450 \text{ nm}$ since it is in a free state the pyrene – quinoline excimer. Addition of ct – DNA resulted in moderate emission quenching (Figure 4C) with preserved shape and maximum of spectrum.

Processing of titration data by means of Scatchard equation^[15] yielded binding constants: (Table 2). Excellent agreement of $\log K_s$ values obtained for **4** in fluorimetric and UV-Vis titration was noted. In general, all studied compounds showed similar, moderate affinity to ct – DNA.

Thermal denaturation experiments revealed negligible stabilisation of ct – DNA by any of studied compounds (Supp. Info.). That excluded intercalative binding mode,^[16] thus suggesting minor groove binding or non – specific electrostatic binding along DNA backbone.

To get better structural insight into **4**, **7**, **8** – ct – DNA complexes, CD spectroscopy was applied as a highly sensitive method for conformational changes in the secondary structure of polynucleotides.^[17] Also, achiral small molecule could upon binding to polynucleotides acquire an induced (ICD) spectrum (usually analysed at range $> 300 \text{ nm}$ at which DNA / RNA does not absorb), which could be helpful for determination of binding modes (intercalation, agglomeration, groove binding, etc.).^[18]

All studied compounds are achiral but intensity of their induced CD spectrum (ICD) in the 230–500 nm range is negligible with respect to CD spectra of ct – DNA, allowing accurate correction of CD titrations. Addition of **4**, **8** to ct – DNA (Figure 5) did not change significantly CD spectrum of DNA (230 – 300 nm range) and also no measurable ICD bands were observed (300 – 400 nm range). Thus, **4**, **8** do not significantly perturb DNA helicity and their




Figure 5. CD titration of ct – DNA ($c = 2 \times 10^{-5} \text{ mol dm}^{-3}$) with **4**, **7** and **8** at molar ratios $r_{[\text{compound}]/[\text{polynucleotide}]} = 0; 0.1; 0.2; 0.3$. Done at pH 7, buffer sodium cacodylate, $I = 0.05 \text{ mol dm}^{-3}$.

chromophores are not uniformly oriented in respect to DNA chiral axis.^[18]

However, conjugate **7** induced moderate change in CD spectrum of DNA (Figure 5). Namely, in the 230–300 nm range all signals shifted toward negative values with increasing ratio $r_{[\text{compound}]/[\text{polynucleotide}]}$. Such systematic drift in broad wavelength range does not agree with a loss of DNA chirality, which is commonly presented by decrease of the absolute CD band intensity (positive CD band at 280 nm becoming less positive and negative CD band at 245 nm becoming less negative).^[18] Such systematic drift in CD spectrum is most likely caused by negative induced ICD band of **7**, which absorbs light in corresponding region (Figure 1). Surprisingly, no significant ICD band in 300–400 nm range was observed. Taking into account that **7** has intramolecularly stacked pyrene and quinoline, obviously principal electronic transitions of such dimeric chromophore in 230–290 nm range are well oriented in respect to DNA chiral axis. Since DNA minor groove can easily accommodate aromatic stacked dimers^[18] and also ICD bands of small molecules in minor groove are usually of strong intensity, minor groove of ct – DNA is most likely binding site of **7**.

CONCLUSIONS

Two novel pyrene – quinoline conjugates (**7** and **8**), showed by their spectrophotometric characteristics to be intramolecularly pre – organised in aqueous solutions, if compared to referent pyrene analogue **4**. Namely, more rigid **7** in water formed intramolecular pyrene – quinoline stacked conformation, characterised by strong hypochromic UV-Vis effect and typical fluorescence of pyrene – quinoline excimer. More

flexible linker in conjugate **8** did not allow such efficient intramolecular stacking as **7**, thus exhibiting much weaker hypochromic UV-Vis effect and only free pyrene fluorescence.

Particularly interesting are fluorimetric titrations results. Pre – organised pyrene – quinoline dimer **7** retained its intramolecular stacking upon DNA binding, thus its characteristic fluorescence only weakly quenched. The pyrene fluorescence of **8** was almost completely quenched (similarly to referent **4**); however, at large excess of DNA over **8** new fluorophore entity was formed within DNA binding site, with fluorescence characteristic for pyrene – quinoline excimer.

All compounds (**4**, **7**, **8**) bind moderately strong to ct – DNA (by $10 \mu\text{mol dm}^{-3}$ affinity) but do not stabilise DNA against thermal denaturation and do not perturb DNA chirality. In addition, CD results suggest that **4** and **8** chromophores are not uniformly oriented in respect to DNA chiral axis, all data taken together excluding intercalation of typical minor groove binding. Thus, **4** and **8** bind by non – organised agglomeration within hydrophobic DNA grooves. At variance to them, **7** showed considerable impact on CD spectrum, attributed to ICD band of intramolecular pyrene – quinoline dimer positioned uniformly within DNA minor groove.^[18]

Here presented results can find applications in supramolecular chemistry, as well as in medicinal chemistry relying on innovative and versatile spectrophotometric probes with fine tuning of intra – and intermolecular interactions. For instance, further *in vitro* studies on a panel of human cell lines would give an insight in intracellular distribution and fluorimetric response of these fluorophores.

Acknowledgment. Authors gratefully acknowledge financial support of ESF project HR.3.2.01 – 0254. IP and IO thank Croatian Science Foundation project 1477 for financial support.

REFERENCES

- [1] M. Demeunynck, C. Bailly, W. D. Wilson, *Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid Complexes*, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, **2004**.
- [2] a) F. M. Winnik, *Chem. Rev.* **1993**, *93*, 587; b) K. Kalyanasundaram, J. K. Thomas, *J. Am. Chem. Soc.* **1977**, *99*, 2039; c) D. C. Dong, M. A. Winnik, *Photochem. Photobiol.* **1982**, *35*, 17.
- [3] a) J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, Kluwer Academic/Plenum, New York, **1999**; b) F. M. Winnik, *Chem. Rev.* **1993**, *93*, 614; c) S. S. Lehrer, *Methods Enzymol.* **1997**, *278*, 286.

- [4] a) P. C. Bevilacqua, R. Kierzek, K. A. Johnson, D. H. Turner, *Science* **1992**, 258, 1358; b) K. Yamana, T. Gokota, H. Ozaki, H. Nakano, O. Sangen, T. Shimidzu, *Nucleosides Nucleotides* **1992**, 11, 383; c) R. Kierzek, Y. Li, D. H. Turner, P. C. Bevilacqua, *J. Am. Chem. Soc.* **1993**, 115, 4985; d) Y. Li, P. C. Bevilacqua, D. Mathews, D. H. Turner, *Biochemistry* **1995**, 34, 14394; e) M. Manoharan, K. L. Tivel, M. Zhao, K. Nafisi, T. L. Netzel, *J. Phys. Chem.* **1995**, 99, 17461; f) J. Yguerabide, E. Talavera, J. M. Alvarez, M. Afkir, *Anal. Biochem.* **1996**, 241, 238; g) J. Dapprich, N. G. Walter, F. Salingue, H. Staerk, *J. Fluoresc.* **1997**, 7, 87; h) R. Preuß, J. Dapprich, N. G. Walter, *J. Mol. Biol.* **1997**, 273, 600; i) K. Yamana, R. Iwase, S. Furutani, H. Tsuchida, H. Zako, T. Yamaoka, A. Murakami, *Nucleic Acids Res.* **1999**, 27, 2387; j) S. K. Silverman, T. R. Cech, *Biochemistry* **1999**, 38, 14224; k) K. Yamana, H. Zako, K. Asazuma, R. Iwase, H. Nakano, A. Murakami, *Angew. Chem.* **2001**, 113, 1138; *Angew. Chem. Int. Ed.* **2001**, 40, 1104; l) V. A. Korshun, D. A. Stetsenko, M. J. Gait, *J. Chem. Soc. Perkin Trans 1* **2002**, 1092.
- [5] a) H. Fritzsche, A. Akhebat, E. Taillandier, K. Rippe, T. M. Jovin, *Nucleic Acids Res.* **1993**, 21, 5085; b) K. Ebata, M. Masuko, H. Ohtani, M. Kashiwasake-Jibu, *Photochem. Photobiol.* **1995**, 62, 836; c) G. Tong, J. M. Lawlor, G. W. Tregear, J. Haralambidis, *J. Am. Chem. Soc.* **1995**, 117, 12151; d) F. D. Lewis, Y. Zhang, R. L. Letsinger, *J. Am. Chem. Soc.* **1997**, 119, 5451; e) K. V. Balakin, V. A. Korshun, I. A. Prokhorenko, G. V. Maleev, I. A. Kudelina, S. V. Gontarev, Y. A. Berlin, *Bioorg. Khim.* **1997**, 23, 33; f) P. L. Paris, J. M. Langenhan, E. T. Kool, *Nucleic Acids Res.* **1998**, 26, 3789; g) K. V. Balakin, V. A. Korshun, I. I. Mikhalev, G. V. Maleev, A. D. Malakhov, I. A. Prokhorenko, Y. A. Berlin, *Biosens. Bioelectron.* **1998**, 13, 771; h) M. Masuko, H. Ohtani, K. Ebata, A. Shimadzu, *Nucleic Acids Res.* **1998**, 26, 5409; i) V. A. Korshun, K. V. Balakin, T. A. Proskurina, I. I. Mikhalev, A. D. Malakhov, Y. A. Berlin, *Nucleosides Nucleotides* **1999**, 18, 2661; j) E. Kostenko, M. Dobrikov, D. Pyshnyi, V. Petyuk, N. Komarova, V. Vlassov, M. Zenkova, *Nucleic Acids Res.* **2001**, 29, 3611; k) A. Mahara, R. Iwase, T. Sakamoto, K. Yamana, T. Yamaoka, A. Murakami, *Angew. Chem.* **2002**, 114, 3800; *Angew. Chem. Int. Ed.* **2002**, 41, 3648.
- [6] a) B. Ravindra Babu, A. K. Prasad, S. Trikha, N. Thorup, V. S. Parmar, J. Wengel, *J. Chem. Soc. Perkin Trans 1*, **2002**, 22, 2509; c) U. B. Christensen, E. B. Pedersen, *Nucleic Acids Res.* **2002**, 30, 4918; d) V. V. Filichev, E. B. Pedersen, *Org. Biomol. Chem.* **2003**, 1, 100; e) J. Michel, K. Bathany, J.-M. Schmitter, J.-P. Monti, S. Moreau, *Tetrahedron* **2002**, 58, 7975.
- [7] K. Groger, D. Baretić, I. Piantanida, M. Marjanović, M. Kralj, M. Grabar, S. Tomić, C. Schmuck, *Org. Biomol. Chem.* **2011**, 9, 198.
- [8] a) L. Hernandez-Folgado, C. Schmuck, S. Tomić, I. Piantanida, *Bioorg. Med. Chem. Lett.* **2008**, 18, 2977; b) J. C. Wu, Y. Zou, C. Y. Li, W. Sicking, I. Piantanida, T. Yi, C. Schmuck, *J. Am. Chem. Soc.* **2012**, 134, 1958.
- [9] J. Matić, L.-M. Tumir, M. Radić Stojković, I. Piantanida, *Curr. Prot. Pep. Sci.* **2016**, 17, 127.
- [10] J. Suć, L. M. Tumir, L. Glavaš-Obrovac, M. Jukić, I. Piantanida, I. Jerić, *Org. Biomol. Chem.* **2016**, 14, 4865.
- [11] L. Delauriere, Z. Y. Dong, K. Laxmi-Reddy, F. Godde, J. J. Toulme, I. Huc, *Angew. Chem. - Int. Ed.* **2012**, 51, 473.
- [12] I. Piantanida, B. S. Palm, P. Čudić, M. Žinić and H. J. Schneider, *Tetrahedron* **2004**, 60, 6225.
- [13] J. L. Mergny, L. Lacroix, *Oligonucleotides* **2003**, 13, 515.
- [14] C. R. Cantor, P. R. Schimmel, *Biophysical Chemistry*, W.H. Freeman and Co., San Francisco, **1980**.
- [15] J. D. McGhee, P. H. V. Hippel, *J. Mol. Biol.* **1974**, 86, 469; G. Scatchard, N. Y. Ann, *Acad. Sci.* **1949**, 51, 660.
- [16] E. C. Long, J. K. Barton, *Acc. Chem. Res.* **1990**, 23, 271.
- [17] A. Rodger, B. Norden, *Circular Dichroism and Linear Dichroism*, Oxford University Press, New York, **1997**.
- [18] M. Eriksson, B. Nordén, *Methods in Enzymology*, Academic Press, San Diego, **2001**.